Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Da-Won Hong"'
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract Despite the common usage of radiotherapy for the treatment of human non-small-cell lung cancer (NSCLC), cancer therapeutic efficacy and outcome with ionizing radiation remains a challenge. Here, we report the antitumor effects and mechanism
Externí odkaz:
https://doaj.org/article/5f51feb4025944279304412ca9ff5d38
Publikováno v:
Experimental and Molecular Medicine, Vol 52, Iss 10, Pp 1730-1743 (2020)
Cancer: Reversing resistance to radiotherapy A novel small molecule drug candidate known as PPZ023 could be a powerful anti-cancer agent due to its ability to overcome the resistance of tumors to radiation therapy. Sung Hee Hong and colleagues at the
Externí odkaz:
https://doaj.org/article/5c60d77527754337ad22d68b6ff7524f
Publikováno v:
Genomics & Informatics, Vol 11, Iss 4, Pp 245-253 (2013)
A radioresistant cell line was established by fractionated ionizing radiation (IR) and assessed by a clonogenic assay, flow cytometry, and Western blot analysis, as well as zymography and a wound healing assay. Microarray was performed to profile glo
Externí odkaz:
https://doaj.org/article/4ecd59611df04560945f14fe50a7226e
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Scientific Reports
Scientific Reports
Despite the common usage of radiotherapy for the treatment of human non-small-cell lung cancer (NSCLC), cancer therapeutic efficacy and outcome with ionizing radiation remains a challenge. Here, we report the antitumor effects and mechanism of a nove
Publikováno v:
Cell Death and Disease, Vol 11, Iss 10, Pp 1-14 (2020)
Cell Death & Disease
Cell Death & Disease
Peroxisome proliferator-activated receptor gamma (PPARγ) is a well-known therapeutic target for type 2 diabetes as well as is a potential target for effective anti-cancer drug, since PPARγ ligands such as ciglitazone (Cig) frequently cause cell dea
Publikováno v:
British Journal of Cancer
Background Peroxisome proliferator-activated receptor γ (PPARγ) agonists frequently induce cell death in human non-small-cell lung cancer (NSCLC) cells. However, majority of NSCLC patients acquire resistance after cancer therapy, and it is still un